Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
OBJECTIVE
Mutations in the BRCA1 and BRCA2 genes confer greater risk of developing breast cancer. We determined whether tumor pathologic features and clinical features differ in patients with and without BRCA mutations.


METHODS
Tumor pathologic features and clinical characteristics were examined in 491 women with breast cancer who underwent genetic testing for BRCA mutations between 1997 and 2006. A retrospective review of medical records was conducted to determine clinical characteristics including ethnicity, age and clinical stage at diagnosis, age at parity, number of full-term pregnancies, use of oral contraceptives and hormone replacement therapy, and BRCA mutation status. Tumor pathology was reviewed to determine histologic type, tumor grade, and estrogen receptor, progesterone receptor, and HER-2/neu status.


RESULTS
Of the 491 patients with identified breast cancers, 391 patients were BRCA negative, and 86 patients were BRCA positive. Triple-negative breast cancer (ie, those with negative estrogen receptor, progesterone receptor, and HER-2/neu status) was diagnosed in 57.1% of the BRCA1-positive patients, 23.3% of the BRCA2-positive patients, and 13.8% of the BRCA-negative patients. BRCA1 mutation carriers had higher nuclear grade tumors than the other two groups (P < .001). Of the triple-negative cancer patients, BRCA2 mutation carriers were older when diagnosed than BRCA1 mutation carriers and noncarriers (P < .01).


CONCLUSIONS
These results suggest that tumors associated with BRCA1 mutations may be divided into two distinct groups, triple-negative and non-triple-negative groups. Future studies should seek to determine whether patients with BRCA1 mutations and triple-negative breast cancer respond to treatment better than BRCA-negative patients with similar tumor pathology.
Atchley
Deann P
DP
Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Albarracin
Constance T
CT
Lopez
Adriana
A
Valero
Vicente
V
Amos
Christopher I
CI
Gonzalez-Angulo
Ana Maria
AM
Hortobagyi
Gabriel N
GN
Arun
Banu K
BK
D001943:Breast Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000473:pathology*; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D009154:Mutation; D012189:Retrospective Studies
Cancer. 1996 Feb 15;77(4):697-709
8616762
Cancer. 1999 May 15;85(10):2200-5
10326698
BMC Cancer. 2005 Jul 04;5:70
15996267
Lancet. 1994 Mar 19;343(8899):692-5
7907678
Breast Cancer Res Treat. 2008 Jul;110(1):99-109
17851763
Eur J Cancer. 1997 Mar;33(3):362-71
9155518
Nature. 2005 Apr 14;434(7035):917-21
15829967
BMC Genomics. 2006 Sep 11;7:231
16965636
J Clin Oncol. 2006 Dec 20;24(36):5652-7
17116942
J Clin Oncol. 2006 Feb 1;24(4):707-15
16446345
Cancer. 1998 Jul 15;83(2):310-9
9669814
Cancer. 1997 Aug 1;80(3):435-41
9241077
Breast Cancer Res Treat. 2008 Mar;108(2):289-96
17492376
Am J Hum Genet. 1998 Mar;62(3):676-89
9497246
BMC Genomics. 2006 Apr 27;7:96
16643655
Breast. 2007 Jun;16(3):280-92
17257844
Nature. 2000 Aug 17;406(6797):747-52
10963602
J Clin Pathol. 2006 Jun;59(6):611-7
16603649
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
17671126
Cancer Res. 1998 May 1;58(9):1839-42
9581822
J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
14519755
J Clin Oncol. 1998 Feb;16(2):397-404
9469321
Cancer Res. 2004 Feb 1;64(3):830-5
14871808
Breast J. 2003 May-Jun;9(3):167-74
12752624